Financial News
MGC Pharmaceuticals "totally understands" CimetrA after MoA study
March 13, 2023 at 08:26 AM EDT
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.
--News Direct--
MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) chief medical officer Nadya Lisovoder speaks to Proactive's Thomas Warner after announcing the completion of an in-vitro pre-clinical mechanism of action (MoA) study for the European based bio-pharma company's CimetrA platform.
Lisovoder says that the fact MGC "totally understands" CimetrA represents a "very important step" in the development process.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
View source version on newsdirect.com: https://newsdirect.com/news/mgc-pharmaceuticals-totally-understands-cimetra-after-moa-study-226216324
Report this content
If you believe this article contains misleading, harmful, or spam content, please let us know.
Report this articleMore News
View More
3 Active ETFs Making Big Moves in August ↗
Today 13:45 EDT
Recent Quotes
View More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
